FIELD: biotechnology.
SUBSTANCE: A Pseudomonas (PE) ectotoxin is proposed with substitution of one or more amino acid residues at L423, F443 and L477 positions. Also a chimeric molecule containing a targeting agent fused to PE and a molecule containing a targeting agent conjugated to PE. In addition, nucleic acids encoding PE and chimeric molecule; a recombinant expression vector; a host cell for PE production; a pharmaceutical composition for cell growth inhibition; a method for cancer treatment or prevention in a mammal; a method for target cell growth inhibition; methods for production of PE, chimeric molecule containing a targeting agent fused to PE, and molecules where PE is covalently bound to the targeting agent are described.
EFFECT: A Pseudomonas exotoxin of this invention exhibits reduced immunogenicity while maintaining cytotoxicity.
23 cl, 12 dwg, 20 tbl, 16 ex
Title | Year | Author | Number |
---|---|---|---|
MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
CHIMERIC ANTIGENIC RECEPTORS TO CD22 | 2012 |
|
RU2644243C2 |
GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
YEAST-BASED IMMUNOTHERAPEUTIC COMPOSITIONS WITH BRACHYURY | 2012 |
|
RU2690180C2 |
M971 CHIMERIC ANTIGEN RECEPTORS | 2013 |
|
RU2658485C2 |
ANTIBODIES AGAINST FACTOR D AND THEIR USE | 2018 |
|
RU2799044C2 |
ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
METHODS FOR TREATMENT OF AUTOIMMUNE DISEASE USING ALLOGENIC T-CELLS | 2017 |
|
RU2773831C2 |
CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
Authors
Dates
2017-08-03—Published
2012-06-07—Filed